SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31 December 2023
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve The Un-Audited Financial Results for the quarter and nine months ended 31 December 2023 SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations
Shilpa Medicare Limited unit 4 , Jadcherla had Europe GMP inspection by AGES, Austria from Jan 22, 2024 to Jan 26, 2024. This inspection has concluded with two minor observations. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Award of Order Receipt of Order
Arbitration Award SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg.
Grant of Code "J" for Pemetrexed Injection, 100mg/10ml, 500mg/50ml, 1000mg/100ml, (NDA) Shilpa Medicare receives approval for Amifampridine tablets
Shilpa Medicare stock rises on NSE SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg.
This is to inform you that Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure. SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate Pursuant to Reg 74(5) of SEBI (Depositories and Participants) Regulation, 2018 . SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice for approval of reclassification from ''Promoter Group'' Category to ''Public'' Category SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window
Intimation of Closure of trading window for the quarter and nine months ended 31 December 2023 SHILPA MEDICARE LTD. - 530549 - Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on December 20, 2023 for Dharmavati Bhutada, Keshav Bhutada & Madhav Bhutada